Letters Open data for all current drugs

A revolution in drug approval practices is required

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8002 (Published 26 November 2012) Cite this as: BMJ 2012;345:e8002
  1. Alastair Mander, geriatrician1
  1. 1Private Practice, Suite 3, Geelong Private Medical Centre, Geelong, VIC 3220 Australia
  1. agmander{at}gmail.com

This is a topic that requires a revolution in practices.1 Currently, when manufacturers submit data to the regulator, they have to provide data on all completed trials. The regulator may ask for further data but once satisfied gives approval or denial for marketing. The data then provided to the public and …

View Full Text

Log in

Log in through your institution


* For online subscription